www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Company releases
      • Company releases
      • Company releases (DK)
      • Subscribe to news
    • Reports & presentations
      • Financial reports
      • Webcasts & presentations
    • Calendar and events
      • Financial calendar and events
      • Annual general meeting
      • Capital Markets Day 2024
    • Share information
      • Share information
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Investor portal
    • Governance
      • Executive Leadership Team
      • Board of Directors
      • Corporate Governance
    • Contact Investor Relations
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Investors

The Share

See all

 


Company releases

See all

  • Post date: 10/12/26
    BSACI 2026: New preference and ease-of-use data comparing EURneffy® nasal adrenaline spray and adrenaline auto-injector trainer devices
    Read more
  • Post date: 10/07/26
    ALK upgrades its full-year outlook on strong tablet sales
    Read more
  • Post date: 09/30/26
    ALK expands strategic tablet supply partnership with Catalent
    Read more
  • Post date: 09/21/26
    ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
    Read more
  • Post date: 09/11/26
    ALK to present at the Morgan Stanley Global Healthcare Conference in New York
    Read more
  • Post date: 08/20/26
    ALK appoints Jacob Glenting as head of Global R&D
    Read more

Featured Events
Aug 20, 2026 at 1:30 PM CEST
Six-month interim report (Q2) 2026
Listen to webcast
Six-month interim report (Q2) 2026
View Presentation

Register for the conference call by using this link and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register on the day before the call at the latest.
Alternative link for webcast (live streaming only)


Read more
Upcoming Events
Nov 17, 2026
Nine-month interim report (Q3) 2026

Read more

Annual report 2025

Read more

 

AGM/Generalforsamling

Read more

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Press
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved